The following enzyme is otherwise called TACE (TNF converting enzyme)
First, I need to recall what TACE does. TNF is tumor necrosis factor, a cytokine involved in inflammation and immune response. The enzyme that processes TNF would be responsible for its cleavage from the cell membrane to become active. I remember that ADAM17 is the enzyme involved here. ADAM stands for A Disintegrin And Metalloproteinase. ADAM17 is known to cleave TNF-α, converting it from a membrane-bound form to a soluble, active form. So the correct answer is ADAM17.
Now, looking at the options (even though they are not provided here), the distractors might include other enzymes like ADAM10, which is involved in processing other substrates like Notch receptors. Another possible distractor could be matrix metalloproteinases (MMPs), which are involved in extracellular matrix degradation but not specifically TNF processing. Also, maybe something like furin, which is a proprotein convertase, but that's more for processing prohormones.
The clinical pearl here is that ADAM17's role in TNF processing makes it a target for drugs like TACE inhibitors, which are used in certain inflammatory diseases. However, these inhibitors can have side effects because ADAM17 has other functions, such as in the shedding of other cell surface proteins.
So putting it all together: TACE is ADAM17. The wrong options are other enzymes not specifically linked to TNF processing. The high-yield fact is ADAM17's role in TNF conversion and its therapeutic implications.
**Core Concept**
The question tests knowledge of enzymes involved in cytokine processing, specifically tumor necrosis factor (TNF) conversion. TNF-α is synthesized as a membrane-bound precursor and requires enzymatic cleavage to become biologically active. This process is mediated by TNF-α converting enzyme (TACE), a member of the ADAM (A Disintegrin And Metalloproteinase) family.
**Why the Correct Answer is Right**
TACE is **ADAM17**, a zinc-dependent metalloproteinase. It cleaves membrane-bound TNF-α to release its soluble form, enabling its pro-inflammatory and apoptotic effects. ADAM17 is ubiquitously expressed and plays critical roles in immune regulation, cell signaling, and disease pathogenesis. Inhibitors of ADAM17 (e.g., TAPIs) are experimental therapies for inflammatory disorders like rheumatoid arthritis.
**Why Each Wrong Option is Incorrect**
**Option A:** *ADAM10* is another metalloproteinase but primarily processes Notch receptors and amyloid precursor protein (APP), not TNF-α.
**Option B:** *MMP-9 (Matrix Metalloproteinase-9)* degrades extracellular matrix components, not TNF-α.
**Option C:** *Furin* is a proprotein convertase that activates precursors like pro-TNF-α, but not the enzyme responsible for its shedding.
**Clinical Pearl / High-Yield Fact**
ADAM17 inhibitors are investigational drugs for TNF-mediated diseases,